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Abstract
Osteogenesis imperfecta (OI) is an uncommon genetic bone disease
associated with brittle bones and fractures in children and adults. Although OI is
most commonly associated with mutations of the genes for type I collagen,
many other genes (some associated with type I collagen processing) have now
been identified. The genetics of OI and advances in our understanding of the
biomechanical properties of OI bone are reviewed in this article. Treatment
includes physiotherapy, fall prevention, and sometimes orthopedic procedures.
In this brief review, we will also discuss current understanding of pharmacologic
therapies for treatment of OI.
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Introduction
Osteogenesis imperfecta (OI) is an unusual heritable disease that 
occurs in about 1 in 10,000 to 20,000 live births1. The major clinical 
manifestation is skeletal fragility. Skeletal deformity, joint laxity, 
and scoliosis may be present2. Other extraskeletal manifestations 
include hearing loss, dentinogenesis imperfecta, blue/gray sclerae, 
hypercalciuria, aortic root dilatation, and neurologic conditions 
such as macrocephaly, hydrocephalus, and basilar invagination1–5. 
The phenotype is variable, ranging from osteoporosis present-
ing in adulthood to lethality in children3. Even adults with “mild” 
OI may have significant musculoskeletal symptoms, including 
arthritis, fractures, back pain, scoliosis, and tendon ruptures6.
About 90% of patients have mutations in type I collagen genes 
(COL1A1 and COL1A2)3; however, many other genes have now 
been described. Some of the genes encode proteins related to type I 
collagen (for example, enzymes that modify type I collagen, chap-
erone proteins, and signaling proteins). In 1979, Sillence et al. 
proposed a classification system for OI with four types based 
on severity: type I mild non-deforming, type II perinatal lethal, 
type III severely deforming, and type IV moderately deforming7. 
This classification has been expanded as new genes were discov-
ered. Phenotypic classification (types I to V with multiple genes 
included in some of the types) has been proposed5. Alternatively, 
classification by genetics has been proposed (see Table 1), which 
was created through modifications of references8–10.
There have been recent advances in the understanding of the 
structure and mechanical properties of bone in children with OI. 
These advances may lead to improved finite element (FE) models 
that help predict fracture risk of specific activities and help plan 
physiotherapy.
In addition to physiotherapy and orthopedic surgery when needed, 
intravenous bisphosphonates have been used extensively in mod-
erate to severe OI in childhood. Less is known about pharmaco-
logic treatment in adults. Anabolic therapy with PTH 1-34 has been 
studied in adults with OI. Future therapies may include antibodies 
to sclerostin, transforming growth factor beta (TGFβ) antagonism, 
gene therapy, and cell-based therapies.
Genes and classification
OI is most commonly caused by mutations in type I collagen. Type 
I collagen is a rod-like structure formed from a trimer of 2 COL1A1 
and 1 COL1A2 subunits3, which requires post-translational modi-
fication. Many of the other rare forms of OI are due to defects in 
Table 1. Classification of osteogenesis imperfecta.
Type Inheritance Gene Protein Defect Phenotype
I AD COLA1/COLA2 α1(1) collagen Collagen quantity Mild, non-deforming
II AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Perinatal lethal
III AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Progressively deforming
IV AD COLA1/COLA2 α1(1)/α2(1) collagen Collagen structure Moderately deforming
V AD IFITM5 BRIL Matrix mineralization Moderate, distinct 
histology
VI AR SERPINF1 PEDF Moderate to severe, 
distinct histology
VII AR CRTAP CRTAP Prolyl 3 hydroxylation Severe to lethal
VIII AR LEPRE1 P3H1 Prolyl 3 hydroxylation Severe to lethal
IX AR PPIB CyPB Prolyl 3 hydroxylation Moderate to lethal
X AR SERPINH1 HSP47 Collagen chaperoning Severe
XI AR FKBP10 FKBP65 Telopeptide hydroxylation Progressively deforming 
(Bruck syndrome)
XII AR SP7 SP7/osterix Osteoblast development Moderate
XIII AR BMP1 BMP1/mTLD Collagen processing Severe, high bone mass
XIV AR TMEM38B TRIC-B Cation channel defect Moderate to severe
XV AR WNT1 WNT1 Variable
XV AD WNT1 WNT1 Early-onset osteoporosis
Others
AR CREB3L1 Oasis COL1A1 transcription Progressively deforming
XL PLS3 Plastin Osteocyte defect Mild
AR PLOD2 Lysyl hydroxylase 2 Collagen telopeptide 
hydroxylation
Progressively deforming
AD, autosomal dominant; AR, autosomal recessive; XL, x-linked.
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proteins involved in cross-linking, hydroxylation, and mineraliza-
tion of type I collagen.
Mutations of CRTAP, which encodes cartilage-associated protein, 
have been shown to cause recessive OI11–14. Mutations of LEPRE1, 
which encodes prolyl 3 hydroxylase14–16, and PPIB (protein cyclo-
phylin B)17–19 also cause recessive OI. The proteins described above 
form a complex that modifies specific prolines in the collagen and 
these mutations result in moderate to lethal OI.
SERPINH1 mutations cause severe recessive OI20. The protein 
affected in SERPINH1 mutations, HSP47, is a collagen chaperone 
protein8. FKBP10 mutations cause recessive OI (progressively 
deforming)21. This gene encodes the protein FKBP65, which 
appears to be needed for hydroxylation of collagen telopetide 
lysine22. Both HSP47 and FKBP65 are needed for the proper fold-
ing of the collagen triple helix. Furthermore, Bruck syndrome 
(OI and congenital contractures) can be caused by homozygous 
mutations on FKPB1023, and Kuskokwim syndrome (congenital 
contractures with mild skeletal problems seen in Yup’ik people in 
Alaska) is caused by FKBP10 mutations24. PLOD2 mutations also 
cause recessive OI25. PLOD-2 encodes lysyl hydroxylase 2, which 
hydroxylates collagen telopeptide lysine. Bruck syndrome can also 
be caused by homozygous mutations of PLOD225.
BMP1 (bone morphogenetic protein 1) mutations also cause reces-
sive OI26,27. The protein, BMP1, is a protease that cleaves the 
c-propeptide of type I collagen26,27 but also has other substrates. 
SP7 mutations cause recessive OI28. SP7 encodes the protein 
osterix, which may be needed for osteoblast differentiation10. WNT1 
mutations29–31 have been reported in early-onset osteoporosis (domi-
nant) and OI (recessive). The protein, WNT1, may be important in 
the beta catenin system, which stimulates bone formation29–31.
TMEM38B mutations have been reported in recessive OI32. This 
gene encodes TRIC-B, which may be important in intracellular cal-
cium signaling. Defective TRIC-B may cause bone disease through 
defective calcium signaling in bone cells10. CREB3L1 mutations 
cause recessive OI33. CREB3L1 encodes the protein OASIS, which 
may activate transcription of COL1A134. PLS3 (plastin 3) muta-
tions have been reported in x-linked osteoporosis35–37. Plastin 3 is 
expressed in osteocyte dendrites and may be important in mechano-
sensing35. Bone biopsies from patients with PLS3 mutations have 
shown cortical and trabecular osteoporosis with normal to low bone 
formation rates36,37. There is no mineralization defect36,37.
Mutations in IFITM5, a bone-restricted IFITM-like protein (BRIL) 
(dominant) cause type V OI38–42. These patients have prominent cal-
lus formation and ossification of the forearm interosseous mem-
brane38–42. They also have mesh-like lamellation on bone biopsy as 
well as a mineralization defect38–42. There appear to be substantial 
differences in phenotypic presentation even with similar muta-
tions40–42. Type VI OI is caused by mutations in SERPINF1 (protein 
PEDF)43,44. Children with type VI OI have elevated alkaline phos-
phatase, and bone biopsy reveals fish-scale pattern under polarized 
light as well as broad bands of unmineralized osteoid43,44. Interest-
ingly, some patients with BRIL mutations have phenotypic type VI 
OI (rather than type V)45. BRIL and PEDF are related, and it appears 
that mutations causing gain-of-function of BRIL cause OI type V 
and that those causing loss-of-function of BRIL look phenotypically 
like OI type VI46.
Structure and mechanical properties of bones in 
osteogenesis imperfecta
From a mechanical perspective, increased fracture risk in indi-
viduals with OI could stem from a combination of reduced bone 
mass, decreased bone material quality, and, in some individuals, the 
presence of bone deformity.
Bone mass
Low bone mass is a clinical characteristic of OI, and individuals 
with this disorder tend to have markedly reduced areal bone min-
eral density (BMD)47–49. This reduced bone mass can be the con-
sequence of decreased bone size or decreased volumetric BMD or 
both49,50. Studies of iliac crest biopsies have revealed lower bone 
tissue quantity in children with moderate and severe OI, including 
reduced bone volume fraction, and decreased trabecular and corti-
cal thicknesses51–53. Decreased bone volume, though less marked, 
was also noted in some children with mild OI51,52.
In cortical bone specimens from the long bone shafts of children 
with OI, “atypical, flattened, and large resorption lacunae”54 and 
abnormally elevated porosity have been observed54–57. For exam-
ple, an average intracortical vascular porosity of 21% was found 
in bone shaft osteotomies from children with OI by synchrotron 
radiation micro-computed tomography55,57; the corresponding value 
in normal pediatric bones was 3%57. From a structural perspec-
tive, reduced bone mass can lead to increased stresses within the 
bone as a result of a smaller area of bone tissue present to sup-
port physiological loads. For this reason, low bone mass is likely a 
considerable contributor to bone fragility in OI.
Bone material quality
In addition to the structural deficiency (low bone mass), mechanical 
quality of the bone material in OI is reduced. The genetic defects 
causing OI affect type I collagen, the main organic component of 
bone. As discussed earlier, most forms of OI (types I to IV) are 
attributed to insufficient collagen production or amino acid substi-
tution defects within the collagen molecules or both58–63, and less 
common recessive forms have been associated with abnormalities 
in other proteins that interact with type I collagen9,64. Since type I 
collagen is an integral component of bone tissues, it should be no 
surprise that abnormalities affecting this protein would impact bone 
material quality. At the ultrastructural level, irregularities in collagen 
and mineral geometry as well as abnormalities in mineral composi-
tion have been reported65–70. Studies in mice indicated that the mate-
rial abnormalities in OI have a negative impact on bone material 
properties71–76. A few studies have also used biopsy and osteotomy 
specimens to measure bone material properties in humans with this 
disorder. Some of these studies used nanoindentation, a technique 
in which a diamond-tip indenter is pressed into the polished surface 
of a material (in this case, bone), creating an indent a few microns 
in size. With this test, elastic modulus and hardness—that is, prop-
erties representing the material’s resistance to elastic (recoverable) 
Page 3 of 10
F1000Research 2015, 4(F1000 Faculty Rev):681 Last updated: 25 MAY 2016
and plastic (non-recoverable) deformation, respectively—are deter-
mined at the submicrostructural level. Based on nanoindentation, 
slightly higher elastic modulus and hardness were found in chil-
dren with mild (type I) versus severe (type III) OI77, whereas these 
properties were not found to differ between children with severe 
(type III) versus moderately severe (type IV) phenotypes78. However, 
exactly how these properties compare with normal tissues remains 
unclear; one study reported higher elastic modulus and hardness in 
children with severe OI versus controls79, whereas another reported 
the opposite80. Furthermore, bone tissues have a complex hierarchi-
cal structure, which results in properties that differ between length 
scales, and nanoindentation provides only limited insight regard-
ing bone tissue properties at the submicrostructural scale. Another 
limitation with this technique is that it does not measure strength, 
a property representing the ability of a material to carry stress 
without breaking or sustaining damage.
Recent studies have measured cortical bone material properties, 
including strength, at a larger scale by using surgical bone specimens 
from long bone diaphyses of children with OI55,56,81. In these stud-
ies, small osteotomy specimens were machined into parallelepiped- 
shaped specimens and loaded to failure in either bending55,81 or 
compression56. Bone material strength was confirmed to be lower 
than normal in these children, and this property was found to be 
negatively related to an abnormally elevated intracortical porosity. 
These findings suggest that increased cortical porosity contributes 
to increased risk of long bone fractures in OI.
Bone deformity
In addition to decreased bone mass and reduced bone material qual-
ity (low bone material strength), deformities of the spine and long 
bones are common in OI. For example, children with severe OI 
often exhibit anterolateral bowing of the femur and anterior bowing 
of the tibia7,47. Increased curvature in long bones leads to an increase 
in maximum stresses within the bone shaft82. The increased stresses 
attributed to bone deformities in OI can further contribute to the risk 
of bone fracture.
Fracture prediction based on mechanical models
Mechanical modeling through the use of FE analysis is a well-
established technique that allows detailed analysis of composite 
structures under a variety of load conditions. In the field of ortho-
pedic biomechanics, FE modeling is frequently used to examine 
the responses of bone to loading83–86. Patient-specific FE models 
have been effective for bone strain and fracture strength assess-
ment, and as recently as 2009 Fritz et al. applied these models 
to predict fractures in OI87,88. A femoral model including muscle 
forces was analyzed during all seven phases of the gait cycle and 
geometrically matched to bone anatomy with x-rays. The most cur-
rent work includes advanced meshing techniques for improved geo-
metric biofidelity and updated mechanical property data55. Other 
FE models for assessing OI bones have also been reported. Orwoll 
et al. used FE modeling to estimate vertebral strength in a study of 
the effects of teriparatide treatment in adults with OI89. Caouette 
et al. developed an FE model to assess fracture risk at the tibia in 
children with OI90. This tibia model examined fracture risk during 
two-legged hopping, lateral loading, and torsional loading. Future 
applications of FE modeling may prove invaluable for better quan-
tification of fracture risk in OI. These models could help identify 
activities that pose greater risk of fracture and, through appropriate 
controls, may enable persons with OI to participate safely and more 
fully in a greater spectrum of daily and recreational activities.
Management
Physical therapy
The goals of the treatment in OI are to decrease pain and fractures 
and to maximize mobility. Physical therapy/rehabilitation91 is par-
ticularly important in children to improve weight bearing and pre-
vent fractures as well as to increase strength and mobility during 
fracture recovery. Some children may require wheelchairs or walk-




Bisphosphonates (BPs) are non-hydrolysable synthetic analogs of 
pyrophosphate92. BPs adhere to mineralized surfaces, inhibit oste-
oclastic bone resorption, and have very long skeletal half-lives92. 
Intravenous BPs are currently the primary treatment of children 
with moderate to severe OI. BPs increase BMD and size in chil-
dren with OI49. BPs do not appear to impair bone formation that 
increases cortical width in children with OI93. Observational studies 
suggest decreased fractures94,95, decreased bone pain, and improved 
vertebral shape94,95. Ability to perform activities of daily living may 
also be improved. However, it has been difficult to confirm all of 
these benefits in randomized trials, and the optimal duration of BP 
treatment is unknown.
In a study of children with predominantly mild OI, oral risedro-
nate increased BMD and appeared to decrease clinical fractures96. 
Atypical fractures have been reported in children with OI treated 
with bisphosphonates97,98; however, osteneocrosis of the jaw does 
not appear to be a major problem in children with OI treated with 
BPs99–101. Several studies have been done on the use of intravenous 
or oral BPs in adults with OI. Although BMD increases have been 
reported during these treatments, fracture data are equivocal102–106. 
A Cochrane review found increased BMD in patients with OI 
treated with BPs but did not find definitive evidence of fracture 
reduction107. Furthermore, a recent meta-analysis of placebo- 
controlled trials suggested that the effects of BPs for fracture pre-
vention in OI were inconclusive108.
Growth hormone
Growth hormone has anabolic effects on bone. A 1-year rand-
omized trial of the BP, neridronate, with or without growth hormone 
showed greater increase in BMD and growth velocity with growth 
hormone, but there was no fracture benefit of growth hormone109.
Teriparatide
Teriparatide (PTH1-34) is an anabolic agent that stimulates bone 
formation (and ultimately bone resorption). This drug decreases 
vertebral and non-vertebral fractures in post-menopausal women 
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with osteoporosis110. Observational data in adults with OI suggest 
increased BMD with teriparatide107,111. Recently, a randomized trial 
of teriparatide in adults with OI showed increased BMD as well as 
increased vertebral strength estimated by FE analysis91. The ben-
efits appeared to occur in mild (type I) OI but not in more severe OI 
(types III and IV).
Denosumab
Denosumab is a monoclonal antibody to receptor activator of 
nuclear factor kappa B ligand that decreases bone resorption, 
increases bone density, and reduces fractures in women with post-
menopausal osteoporosis112. This drug may represent a future ther-
apy in OI. In a study of four children with type VI OI, increased 
BMD and mobility and improved vertebral shape were reported 
after denosumab treatment, and the outcomes of this study indi-
cated that this treatment appears to be safe113. There is also a report 
of denosumab use in two children with OI caused by COL1A1/A2 
mutations114. As with BPs, “zebra lines” were present, suggesting 
continued longitudinal growth114. Denosumab has been reported to 
cause hypophosphatemia, hypocalcemia, and secondary hyperpar-
athyroidism in a child with fibrous dysplasia of bone115. There was 
rebound hypercalcemia after stopping denosumab115.
Possible future therapies
Sclerostin is an inhibitor of the LRP5/WnT system that decreases 
bone formation. Antibodies to sclerostin are in clinical trials for 
treatment of osteoporosis with the goal to increase bone density116. 
Sclerostin antibody appeared to be effective in a mouse model of 
moderately severe OI117,118 but less so in a mouse model of more 
severe OI119. TGFβ is secreted by osteoblasts and increases osteo-
clastic bone resorption120. Excessive TGFβ signaling may be impor-
tant in some forms of OI, and anti-TGFβ therapy represents an 
interesting prospect for the future treatment of OI120.
Cell-based therapy, such as bone marrow121 or mesenchymal stem 
cell122–124 transplantation, has also been investigated and may have 
promise; but these could also have significant risks. Gene therapy 
with allele-specific silencing may represent a future therapy125.
Summary
Although most cases of OI are caused by COL1A1/A2 mutations, 
many new genetic causes have been identified in recent years. Some 
of these genes are related to the processing of type I collagen. Fur-
thermore, we have greater understanding of the biomechanics of OI 
bone, including material properties, muscle and gait load effects, 
and fracture strength assessment. Biomechanical models could help 
identify activities that pose greater risk of fracture and, through 
appropriate controls, may enable persons with OI to participate 
safely and more fully in a greater spectrum of activities. Physical 
therapy is an important part of the management of these patients. 
Intravenous BPs are commonly used in children with moderate to 
severe OI. Some of the benefits seen in observational studies have 
been hard to prove in controlled studies. Treatment of adults with OI 
is less well studied. BPs and teriparatide appear to increase BMD, 
but fracture data are lacking. Teriparatide appears to increase bone 
strength as estimated by FE analysis in adults with mild OI. Other 
promising treatments for OI are under investigation.
Competing interests
JS is a consultant for Alexion Pharmaceuticals. The other authors 
declare that they have no competing interests.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
References F1000 recommended
1. Monti E, Mottes M, Fraschini P, et al.: Current and emerging treatments for 
the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010; 6: 
367–81.  
PubMed Abstract | Publisher Full Text | Free Full Text 
2. Arponen H, Mäkitie O, Waltimo-Sirén J: Association between joint hypermobility, 
scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta 
patients: a retrospective cross-sectional study. BMC Musculoskelet Disord. 
2014; 15: 428.  
PubMed Abstract | Publisher Full Text | Free Full Text 
3. Lindahl K, Langdahl B, Ljunggren Ö, et al.: Treatment of osteogenesis imperfecta 
in adults. Eur J Endocrinol. 2014; 171(2): R79–90.  
PubMed Abstract | Publisher Full Text 
4. Lamanna A, Fayers T, Clarke S, et al.: Valvular and aortic diseases in 
osteogenesis imperfecta. Heart Lung Circ. 2013; 22(10): 801–10.  
PubMed Abstract | Publisher Full Text 
5. Biggin A, Munns CF: Osteogenesis imperfecta: diagnosis and treatment. Curr 
Osteoporos Rep. 2014; 12(3): 279–88.  
PubMed Abstract | Publisher Full Text 
6. McKiernan FE: Musculoskeletal manifestations of mild osteogenesis 
imperfecta in the adult. Osteoporos Int. 2005; 16(12): 1698–702.  
PubMed Abstract | Publisher Full Text 
7. Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis 
imperfecta. J Med Genet. 1979; 16(2): 101–16.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. Valadares ER, Carneiro TB, Santos PM, et al.: What is new in genetics and 
osteogenesis imperfecta classification? J Pediatr (Rio J). 2014; 90(6): 536–41. 
PubMed Abstract | Publisher Full Text 
9. Forlino A, Cabral WA, Barnes AM, et al.: New perspectives on osteogenesis 
imperfecta. Nat Rev Endocrinol. 2011; 7(9): 540–57.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Marini JC, Reich A, Smith SM: Osteogenesis imperfecta due to mutations in 
non-collagenous genes: lessons in the biology of bone formation. Curr Opin 
Pediatr. 2014; 26(4): 500–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11.  Barnes AM, Chang W, Morello R, et al.: Deficiency of cartilage-associated 
protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006; 
355(26): 2757–64.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
12.  Morello R, Bertin TK, Chen Y, et al.: CRTAP is required for prolyl 3- hydroxylation 
and mutations cause recessive osteogenesis imperfecta. Cell. 2006; 127(2): 
291–304.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
13. Baldridge D, Schwarze U, Morello R, et al.: CRTAP and LEPRE1 mutations in 
recessive osteogenesis imperfecta. Hum Mutat. 2008; 29(12): 1435–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Marini JC, Cabral WA, Barnes AM: Null mutations in LEPRE1 and CRTAP cause 
severe recessive osteogenesis imperfecta. Cell Tissue Res. 2010; 339(1): 59–70. 
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 5 of 10
F1000Research 2015, 4(F1000 Faculty Rev):681 Last updated: 25 MAY 2016
15. Pepin MG, Schwarze U, Singh V, et al.: Allelic background of LEPRE1 
mutations that cause recessive forms of osteogenesis imperfecta in different 
populations. Mol Genet Genomic Med. 2013; 1(4): 194–205.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16.  Cabral WA, Chang W, Barnes AM, et al.: Prolyl 3-hydroxylase 1 deficiency 
causes a recessive metabolic bone disorder resembling lethal/severe 
osteogenesis imperfecta. Nat Genet. 2007; 39(3): 359–65.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
17. van Dijk FS, Nesbitt IM, Zwikstra EH, et al.: PPIB mutations cause severe 
osteogenesis imperfecta. Am J Hum Genet. 2009; 85(4): 521–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Barnes AM, Carter EM, Cabral WA, et al.: Lack of cyclophilin B in osteogenesis 
imperfecta with normal collagen folding. N Engl J Med. 2010; 362(6): 521–8. 
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Pyott SM, Schwarze U, Christiansen HE, et al.: Mutations in PPIB (cyclophilin 
B) delay type I procollagen chain association and result in perinatal lethal to 
moderate osteogenesis imperfecta phenotypes. Hum Mol Genet. 2011; 20(8): 
1595–609.  
PubMed Abstract | Publisher Full Text | Free Full Text 
20.  Christiansen HE, Schwarze U, Pyott SM, et al.: Homozygosity for a missense 
mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, 
results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010; 
86(3): 389–98.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
21.  Alanay Y, Avaygan H, Camacho N, et al.: Mutations in the gene encoding the 
RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta.  
Am J Hum Genet. 2010; 86(4): 551–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
22. Barnes AM, Cabral WA, Weis M, et al.: Absence of FKBP10 in recessive type 
XI osteogenesis imperfecta leads to diminished collagen cross-linking and 
reduced collagen deposition in extracellular matrix. Hum Mutat. 2012; 33(11): 
1589–98.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Kelley BP, Malfait F, Bonafe L, et al.: Mutations in FKBP10 cause recessive 
osteogenesis imperfecta and Bruck syndrome. J Bone Miner Res. 2011; 26(3): 
666–72.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Barnes AM, Duncan G, Weis M, et al.: Kuskokwim syndrome, a recessive 
congenital contracture disorder, extends the phenotype of FKBP10 mutations. 
Hum Mutat. 2013; 34(9): 1279–88.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25. Puig-Hervás MT, Temtamy S, Aglan M, et al.: Mutations in PLOD2 cause 
autosomal-recessive connective tissue disorders within the Bruck  
syndrome--osteogenesis imperfecta phenotypic spectrum. Hum Mutat. 2012; 
33(10): 1444–9.  
PubMed Abstract | Publisher Full Text 
26.  Martínez-Glez V, Valencia M, Caparrós-Martín JA, et al.: Identification of 
a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal 
recessive osteogenesis imperfecta. Hum Mutat. 2012; 33(2): 343–50.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
27. Valencia M, Caparrós-Martin JA, Sirerol-Piquer MS, et al.: Report of a newly 
identified patient with mutations in BMP1 and underlying pathogenetic 
aspects. Am J Med Genet A. 2014; 164A(5): 1143–50.  
PubMed Abstract | Publisher Full Text 
28.  Lapunzina P, Aglan M, Temtamy S, et al.: Identification of a frameshift 
mutation in Osterix in a patient with recessive osteogenesis imperfecta.  
Am J Hum Genet. 2010; 87(1): 110–4.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
29.  Keupp K, Beleggia F, Kayserili H, et al.: Mutations in WNT1 cause different 
forms of bone fragility. Am J Hum Genet. 2013; 92(4): 565–74.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
30.  Pyott SM, Tran TT, Leistritz DF, et al.: WNT1 mutations in families affected 
by moderately severe and progressive recessive osteogenesis imperfecta.  
Am J Hum Genet. 2013; 92(4): 590–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
31.  Laine CM, Joeng KS, Campeau PM, et al.: WNT1 mutations in early-onset 
osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013; 368(19):  
1809–16.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation
32.  Shaheen R, Alazami AM, Alshammari MJ, et al.: Study of autosomal 
recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by 
TMEM38B mutation. J Med Genet. 2012; 49(10): 630–5.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
33. Symoens S, Malfait F, D'hondt S, et al.: Deficiency for the ER-stress transducer 
OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet 
J Rare Diss. 2013; 8: 154.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34.  Murakami T, Saito A, Hino S, et al.: Signalling mediated by the endoplasmic 
reticulum stress transducer OASIS is involved in bone formation. Nat cell biol. 
2009; 11(10): 1205–11.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
35.  van Dijk FS, Zillikens MC, Micha D, et al.: PLS3 mutations in X-linked 
osteoporosis with fractures. N Engl J Med. 2013; 369(16): 1529–36.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
36. Fahiminiya S, Majewski J, Al-Jallad H, et al.: Osteoporosis caused by mutations 
in PLS3: clinical and bone tissue characteristics. J Bone Miner Res. 2014; 29(8): 
1805–14.  
PubMed Abstract | Publisher Full Text 
37. Laine CM, Wessman M, Toiviainen-Salo S, et al.: A novel splice mutation in PLS3 
causes X-linked early onset low-turnover osteoporosis. J Bone Miner Res. 
2015; 30(3): 510–8.  
PubMed Abstract | Publisher Full Text 
38.  Cho TJ, Lee KE, Lee SK: A single recurrent mutation in the 5'-UTR of 
IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012; 91(2): 
343–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
39.  Semler O, Garbes L, Keupp K, et al.: A mutation in the 5'-UTR of 
IFITM5 creates an in-frame start codon and causes autosomal-dominant 
osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 
2012; 91(2): 349–57.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
40. Grover M, Campeau PM, Lietman CD, et al.: Osteogenesis imperfecta without 
features of type V caused by a mutation in the IFITM5 gene. J Bone Miner Res. 
2013; 28(11): 2333–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41.  Shapiro JR, Lietman C, Grover M, et al.: Phenotypic variability of 
osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner 
Res. 2013; 28(7): 1523–30.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
42.  Rauch F, Moffatt P, Cheung M, et al.: Osteogenesis imperfecta type V: 
marked phenotypic variability despite the presence of the IFITM5  
c.-14C>T mutation in all patients. J Med Genet. 2013; 50(1): 21–4.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
43.  Becker J, Semler O, Gilissen C, et al.: Exome sequencing identifies 
truncating mutations in human SERPINF1 in autosomal-recessive 
osteogenesis imperfecta. Am J Hum Genet. 2011; 88(3): 362–71.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
44. Homan EP, Rauch F, Grafe I, et al.: Mutations in SERPINF1 cause osteogenesis 
imperfecta type VI. J Bone Miner Res. 2011; 26(12): 2798–803.  
PubMed Abstract | Publisher Full Text | Free Full Text 
45.  Guillén-Navarro E, Ballesta-Martínez MJ, Valencia M, et al.: Two mutations in 
IFITM5 causing distinct forms of osteogenesis imperfecta. Am J Med Genet A. 
2014; 164A(5): 1136–42.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
46.  Farber CR, Reich A, Barnes AM, et al.: A novel IFITM5 mutation in severe 
atypical osteogenesis imperfecta type VI impairs osteoblast production 
of pigment epithelium-derived factor. J Bone Miner Res. 2014; 29(6): 
1402–11. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
47. Renaud A, Aucourt J, Weill J, et al.: Radiographic features of osteogenesis 
imperfecta. Insights imaging. 2013; 4(4): 417–29.  
PubMed Abstract | Publisher Full Text | Free Full Text 
48. Kusumi K, Ayoob R, Bowden SA, et al.: Beneficial effects of intravenous 
pamidronate treatment in children with osteogenesis imperfecta under 24 
months of age. J Bone Miner Metab. 2014.  
PubMed Abstract | Publisher Full Text 
49. Rauch F, Plotkin H, Zeitlin L, et al.: Bone mass, size, and density in children and 
adolescents with osteogenesis imperfecta: effect of intravenous pamidronate 
therapy. J Bone Miner Res. 2003; 18(4): 610–4.  
PubMed Abstract | Publisher Full Text 
50. Rauch F, Tutlewski B, Schönau E, et al.: The bone behind a low areal bone 
mineral density: peripheral quantitative computed tomographic analysis in a 
woman with osteogenesis imperfecta. J Musculoskelet Neuronal Interact. 2002; 
2(4): 306–8.  
PubMed Abstract 
51. Jones SJ, Glorieux FH, Travers R, et al.: The microscopic structure of bone in 
normal children and patients with osteogenesis imperfecta: a survey using 
backscattered electron imaging. Calcif Tissue Int. 1999; 64(1): 8–17.  
PubMed Abstract | Publisher Full Text 
52. Rauch F, Travers R, Parfitt AM, et al.: Static and dynamic bone histomorphometry 
in children with osteogenesis imperfecta. Bone. 2000; 26(6): 581–9.  
PubMed Abstract | Publisher Full Text 
53. Roschger P, Fratzl-Zelman N, Misof BM, et al.: Evidence that abnormal high 
bone mineralization in growing children with osteogenesis imperfecta is not 
associated with specific collagen mutations. Calcif Tissue Int. 2008; 82(4): 
263–70.  
PubMed Abstract | Publisher Full Text 
54. Pazzaglia UE, Congiu T, Brunelli PC, et al.: The long bone deformity of 
osteogenesis imperfecta III: analysis of structural changes carried out with 
scanning electron microscopic morphometry. Calcif Tissue Int. 2013; 93(5): 
453–61.  
PubMed Abstract | Publisher Full Text 
Page 6 of 10
F1000Research 2015, 4(F1000 Faculty Rev):681 Last updated: 25 MAY 2016
55. Albert C, Jameson J, Smith P, et al.: Reduced diaphyseal strength associated 
with high intracortical vascular porosity within long bones of children with 
osteogenesis imperfecta. Bone. 2014; 66: 121–30.  
PubMed Abstract | Publisher Full Text | Free Full Text 
56. Vardakastani V, Saletti D, Skalli W, et al.: Increased intra-cortical porosity 
reduces bone stiffness and strength in pediatric patients with osteogenesis 
imperfecta. Bone. 2014; 69: 61–7.  
PubMed Abstract | Publisher Full Text 
57. Jameson JR, Albert CI, Busse B, et al.: 3D micron-scale imaging of the cortical 
bone canal network in human osteogenesis imperfecta (OI). In Proceedings 
of SPIE, Medical Imaging 2013: Biomedical Applications in Molecular, Structural, 
and Functional Imaging. JB Weaver and RC Molthen, Editors. 2013, International 
Society for Optics and Photonics: Lake Buena Vista, FL. 2013; 8672.  
Publisher Full Text 
58. Wenstrup RJ, Willing MC, Starman BJ, et al.: Distinct biochemical phenotypes 
predict clinical severity in nonlethal variants of osteogenesis imperfecta.  
Am J Hum Genet. 1990; 46(5): 975–82.  
PubMed Abstract | Free Full Text 
59. Byers PH, Wallis GA, Willing MC: Osteogenesis imperfecta: translation of 
mutation to phenotype. J Med Genet. 1991; 28(7): 433–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
60. Marini JC, Forlino A, Cabral WA, et al.: Consortium for osteogenesis imperfecta 
mutations in the helical domain of type I collagen: regions rich in lethal 
mutations align with collagen binding sites for integrins and proteoglycans. 
Hum Mutat. 2007; 28(3): 209–21.  
PubMed Abstract | Publisher Full Text | Free Full Text 
61. Barsh GS, David KE, Byers PH: Type I osteogenesis imperfecta: a nonfunctional 
allele for pro alpha 1 (I) chains of type I procollagen. Proc Natl Acad Sci U S A. 
1982; 79(12): 3838–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
62. Sykes B, Francis MJ, Smith R: Altered relation of two collagen types in 
osteogenesis imperfecta. N Engl J Med. 1977; 296(21): 1200–3.  
PubMed Abstract | Publisher Full Text 
63. Willing MC, Deschenes SP, Scott DA, et al.: Osteogenesis imperfecta type I: 
molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum 
Genet. 1994; 55(4): 638–47.  
PubMed Abstract | Free Full Text 
64. Shapiro JR: Clinical and genetic classification of osteogenesis imperfecta and 
epidemiology. In Osteogenesis imperfecta - a translational approach to brittle bone 
disease. JR Shapiro, et al., Editors. Academic Press: San Diego, CA. 2014: 15–22. 
Publisher Full Text 
65. Cassella JP, Ali SY: Abnormal collagen and mineral formation in osteogenesis 
imperfecta. Bone Miner. 1992; 17(2): 123–8.  
PubMed Abstract | Publisher Full Text 
66. Cassella JP, Barber P, Catterall AC, et al.: A morphometric analysis of osteoid 
collagen fibril diameter in osteogenesis imperfecta. Bone. 1994; 15(3): 329–34. 
PubMed Abstract | Publisher Full Text 
67. Stöss H, Freisinger P: Collagen fibrils of osteoid in osteogenesis imperfecta: 
morphometrical analysis of the fibril diameter. Am J Med Genet. 1993; 45(2): 
257.  
PubMed Abstract | Publisher Full Text 
68. Vetter U, Eanes ED, Kopp JB, et al.: Changes in apatite crystal size in bones of 
patients with osteogenesis imperfecta. Calcif Tissue Int. 1991; 49(4): 248–50. 
PubMed Abstract | Publisher Full Text 
69. Traub W, Arad T, Vetter U, et al.: Ultrastructural studies of bones from patients 
with osteogenesis imperfecta. Matrix Biol. 1994; 14(4): 337–45.  
PubMed Abstract | Publisher Full Text 
70. Fratzl-Zelman N, Schmidt I, Roschger P, et al.: Unique micro- and nano-scale 
mineralization pattern of human osteogenesis imperfecta type VI bone. Bone. 
2015; 73: 233–41.  
PubMed Abstract | Publisher Full Text 
71. Kozloff KM, Carden A, Bergwitz C, et al.: Brittle IV mouse model for osteogenesis 
imperfecta IV demonstrates postpubertal adaptations to improve whole bone 
strength. J Bone Miner Res. 2004; 19(4): 614–22.  
PubMed Abstract | Publisher Full Text 
72. Jepsen KJ, Schaffler MB, Kuhn JL, et al.: Type I collagen mutation alters the 
strength and fatigue behavior of Mov13 cortical tissue. J Biomech. 1997; 
30(11–12): 1141–7.  
PubMed Abstract | Publisher Full Text 
73. McCarthy EA, Raggio CL, Hossack MD, et al.: Alendronate treatment for infants 
with osteogenesis imperfecta: demonstration of efficacy in a mouse model. 
Pediatr Res. 2002; 52(5): 660–70.  
PubMed Abstract | Publisher Full Text 
74. Misof BM, Roschger P, Baldini T, et al.: Differential effects of alendronate 
treatment on bone from growing osteogenesis imperfecta and wild-type 
mouse. Bone. 2005; 36(1): 150–8.  
PubMed Abstract | Publisher Full Text 
75. Miller E, Delos D, Baldini T, et al.: Abnormal mineral-matrix interactions are a 
significant contributor to fragility in oim/oim bone. Calcif Tissue Int. 2007; 81(3): 
206–14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
76. Rao SH, Evans KD, Oberbauer AM, et al.: Bisphosphonate treatment in the oim 
mouse model alters bone modeling during growth. J Biomech. 2008; 41(16): 
3371–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
77. Albert C, Jameson J, Toth JM, et al.: Bone properties by nanoindentation in mild 
and severe osteogenesis imperfecta. Clin Biomech (Bristol, Avon). 2013; 28(1): 
110–6.  
PubMed Abstract | Publisher Full Text 
78. Fan Z, Smith PA, Harris GF, et al.: Comparison of nanoindentation 
measurements between osteogenesis imperfecta Type III and Type IV and 
between different anatomic locations (femur/tibia versus iliac crest). Connect 
Tissue Res. 2007; 48(2): 70–5.  
PubMed Abstract | Publisher Full Text 
79. Weber M, Roschger P, Fratzl-Zelman N, et al.: Pamidronate does not adversely 
affect bone intrinsic material properties in children with osteogenesis 
imperfecta. Bone. 2006; 39(3): 616–22.  
PubMed Abstract | Publisher Full Text 
80. Imbert L, Aurégan J, Pernelle K, et al.: Mechanical and mineral properties of 
osteogenesis imperfecta human bones at the tissue level. Bone. 2014; 65: 
18–24.  
PubMed Abstract | Publisher Full Text 
81. Albert CI, Jameson J, Harris G: Design and validation of bending test method 
for characterization of miniature pediatric cortical bone specimens. Proc Inst 
Mech Eng H. 2013; 227(2): 105–13.  
PubMed Abstract | Publisher Full Text 
82. Fritz JM, Grosland NM, Smith PA, et al.: Brittle bone fracture risk with transverse 
isotropy. In Proceedings of the 37th Annual Meeting of the American Society of 
Biomechanics. September 4–7. Omaha, NE, 2013.  
Reference Source
83. Boyd SK, Müller R: Smooth surface meshing for automated finite element 
model generation from 3D image data. J Biomech. 2006; 39(7): 1287–95. 
PubMed Abstract | Publisher Full Text 
84. Shim VB, Pitto RP, Streicher RM, et al.: The use of sparse CT datasets for  
auto-generating accurate FE models of the femur and pelvis. J Biomech. 2007; 
40(1): 26–35.  
PubMed Abstract | Publisher Full Text 
85. Edwards WB, Troy KL: Simulating distal radius fracture strength using 
biomechanical tests: a modeling study examining the influence of boundary 
conditions. J Biomech Eng. 2011; 133(11): 114501.  
PubMed Abstract | Publisher Full Text 
86. Edwards WB, Troy KL: Finite element prediction of surface strain and fracture 
strength at the distal radius. Med Eng Phys. 2012; 34(3): 290–8.  
PubMed Abstract | Publisher Full Text 
87. Fritz JM, Guan Y, Wang M, et al.: A fracture risk assessment model of the femur 
in children with osteogenesis imperfecta (OI) during gait. Med Eng Phys. 2009; 
31(9): 1043–8.  
PubMed Abstract | Publisher Full Text 
88. Fritz JM, Guan Y, Wang M, et al.: Muscle force sensitivity of a finite element 
fracture risk assessment model in osteogenesis imperfecta - biomed 2009. 
Biomed Sci Instrum. 2009; 45: 316–21.  
PubMed Abstract 
89.  Orwoll ES, Shapiro J, Veith S, et al.: Evaluation of teriparatide treatment in 
adults with osteogenesis imperfecta. J Clin Invest. 2014; 124(2): 491–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
90.  Caouette C, Rauch F, Villemure I, et al.: Biomechanical analysis of fracture 
risk associated with tibia deformity in children with osteogenesis imperfecta: 
a finite element analysis. J Musculoskelet Neuronal Interact. 2014; 14(2): 205–12. 
PubMed Abstract | F1000 Recommendation 
91.  Hoyer-Kuhn H, Semler O, Stark C, et al.: A specialized rehabilitation 
approach improves mobility in children with osteogenesis imperfecta.  
J Musculoskelet Neuronal Interact. 2014; 14(4): 445–53.  
PubMed Abstract | F1000 Recommendation 
92. Licata AA: Discovery, clinical development, and therapeutic uses of 
bisphosphonates. Ann Pharmacother. 2005; 39(4): 668–77.  
PubMed Abstract | Publisher Full Text 
93. Rauch F, Travers R, Plotkin H, et al.: The effects of intravenous pamidronate on 
the bone tissue of children and adolescents with osteogenesis imperfecta.  
J Clin Invest. 2002; 110(9): 1293–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
94. Plotkin H, Rauch F, Bishop NJ, et al.: Pamidronate treatment of severe 
osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol 
Metab. 2000; 85(5): 1846–50.  
PubMed Abstract | Publisher Full Text 
95. Land C, Rauch F, Munns CF, et al.: Vertebral morphometry in children and 
adolescents with osteogenesis imperfecta: effect of intravenous pamidronate 
treatment. Bone. 2006; 39(4): 901–6.  
PubMed Abstract | Publisher Full Text 
96.  Bishop N, Adami S, Ahmed SF, et al.: Risedronate in children with 
osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. 
Lancet. 2013; 382(9902): 1424–32.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
Page 7 of 10
F1000Research 2015, 4(F1000 Faculty Rev):681 Last updated: 25 MAY 2016
97. Nicolaou N, Agrawal Y, Padman M, et al.: Changing pattern of femoral fractures 
in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child 
Orthop. 2012; 6(1): 21–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
98. Carpintero P, Del Fresno JA, Ruiz-Sanz J, et al.: Atypical fracture in a child with 
osteogenesis imperfecta. Joint Bone Spine. 2015; 82(4): 287–8.  
PubMed Abstract | Publisher Full Text 
99. Malmgren B, Aström E, Söderhäll S: No osteonecrosis in jaws of young patients 
with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 
2008; 37(4): 196–200.  
PubMed Abstract | Publisher Full Text 
100. Chahine C, Cheung MS, Head TW, et al.: Tooth extraction socket healing in 
pediatric patients treated with intravenous pamidronate. J Pediatr. 2008; 153(5): 
719–20.  
PubMed Abstract | Publisher Full Text 
101. Hennedige AA, Jayasinghe J, Khajeh J, et al.: Systematic review on the incidence 
of bisphosphonate related osteonecrosis of the jaw in children diagnosed with 
osteogenesis imperfecta. J Oral Maxillofac Res. 2014; 4(4): e1.  
PubMed Abstract | Free Full Text 
102. Adami S, Gatti D, Colapietro F, et al.: Intravenous neridronate in adults with 
osteogenesis imperfecta. J Bone Miner Res. 2003; 18(1): 126–30.  
PubMed Abstract | Publisher Full Text 
103. Chevrel G, Schott AM, Fontanges E, et al.: Effects of oral alendronate on  
BMD in adult patients with osteogenesis imperfecta: a 3-year randomized 
placebo-controlled trial. J Bone Miner Res. 2006; 21(2): 300–6.  
PubMed Abstract | Publisher Full Text 
104. Shapiro JR, Thompson CB, Wu Y, et al.: Bone mineral density and fracture rate 
in response to intravenous and oral bisphosphonates in adult osteogenesis 
imperfecta. Calcif Tissue Int. 2010; 87(2): 120–9.  
PubMed Abstract | Publisher Full Text 
105. Bradbury LA, Barlow S, Geoghegan F, et al.: Risedronate in adults with 
osteogenesis imperfecta type I: increased bone mineral density and 
decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012; 
23(1): 285–94.  
PubMed Abstract | Publisher Full Text 
106. O'Sullivan ES, van der Kamp S, Kilbane M, et al.: Osteogenesis imperfecta in 
adults: phenotypic characteristics and response to treatment in an Irish 
cohort. Ir J Med Sci. 2014; 183(2): 225–30.  
PubMed Abstract | Publisher Full Text 
107.  Phillipi CA, Remmington T, Steiner RD: Bisphosphonate therapy for 
osteogenesis imperfecta. Cochrane Database Syst Rev. 2008; (4): CD005088. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
108.  Hald JD, Evangelou E, Langdahl BL, et al.: Bisphosphonates for the 
prevention of fractures in osteogenesis imperfecta: meta-analysis of  
placebo-controlled trials. J Bone Miner Res. 2015; 30(5): 929–33.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
109.  Antoniazzi F, Monti E, Venturi G, et al.: GH in combination with 
bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010; 
163(3): 479–87.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
110. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone  
(1-34) on fractures and bone mineral density in postmenopausal women with 
osteoporosis. N Engl J Med. 2001; 344(19): 1434–41.  
PubMed Abstract | Publisher Full Text 
111.  Gatti D, Rossini M, Viapiana O, et al.: Teriparatide treatment in adult patients 
with osteogenesis imperfecta type I. Calcif Tissue Int. 2013; 93(5): 448–52. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
112.  Cummings SR, San Martin J, McClung MR, et al.: Denosumab for prevention 
of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 
361(8): 756–65.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
113.  Hoyer-Kuhn H, Netzer C, Koerber F, et al.: Two years’ experience with 
denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare 
Dis. 2014; 9: 145.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
114. Hoyer-Kuhn H, Semler O, Schoenau E: Effect of denosumab on the growing 
skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab. 2014; 99(11): 
3954–5.  
PubMed Abstract | Publisher Full Text 
115. Boyce AM, Chong WH, Yao J, et al.: Denosumab treatment for fibrous dysplasia. 
J Bone Miner Res. 2012; 27(7): 1462–70.  
PubMed Abstract | Publisher Full Text | Free Full Text 
116.  McClung MR, Grauer A, Boonen S, et al.: Romosozumab in postmenopausal 
women with low bone mineral density. N Engl J Med. 2014; 370(5): 412–20. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
117.  Sinder BP, Eddy MM, Ominsky MS, et al.: Sclerostin antibody improves 
skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.  
J Bone Miner Res. 2013; 28(1): 73–80.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
118.  Sinder BP, White LE, Salemi JD, et al.: Adult Brtl/+ mouse model of 
osteogenesis imperfecta demonstrates anabolic response to sclerostin 
antibody treatment with increased bone mass and strength. Osteoporos Int. 
2014; 25(8): 2097–107.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
119.  Roschger A, Roschger P, Keplingter P, et al.: Effect of sclerostin antibody 
treatment in a mouse model of severe osteogenesis imperfecta. Bone. 2014; 
66: 182–8.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
120.  Grafe I, Yang T, Alexander S, et al.: Excessive transforming growth factor-β 
signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014; 
20(6): 670–5.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
121. Horwitz EM, Prockop DJ, Gordon PL, et al.: Clinical responses to bone marrow 
transplantation in children with severe osteogenesis imperfecta. Blood. 2001; 
97(5): 1227–31.  
PubMed Abstract | Publisher Full Text 
122.  Horwitz EM, Gordon PL, Koo WK, et al.: Isolated allogeneic bone  
marrow-derived mesenchymal cells engraft and stimulate growth in children 
with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl 
Acad Sci U S A. 2002; 99(13): 8932–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
123.  Le Blanc K, Götherström C, Ringdén O, et al.: Fetal mesenchymal stem-cell 
engraftment in bone after in utero transplantation in a patient with severe 
osteogenesis imperfecta. Transplantation. 2005; 79(11): 1607–14.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
124. Amin MT, Shazly SA: In utero stem cell transplantation for radical treatment of 
osteogenesis imperfecta: perspectives and controversies. Am J Perinatol. 2014; 
31(10): 829–36.  
PubMed Abstract | Publisher Full Text 
125.  Lindahl K, Kindmark A, Laxman N, et al.: Allele dependent silencing of 
collagen type I using small interfering RNAs targeting 3’UTR Indels - a novel 
therapeutic approach in osteogenesis imperfecta. Int J Med Sci. 2013; 10(10): 
1333–43.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
Page 8 of 10
F1000Research 2015, 4(F1000 Faculty Rev):681 Last updated: 25 MAY 2016
F1000Research
Open Peer Review
   Current Referee Status:
Version 1
 07 September 2015Referee Report
doi:10.5256/f1000research.6864.r10219
 Bart Clarke
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine,
Rochester, MN, USA
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 07 September 2015Referee Report
doi:10.5256/f1000research.6864.r10218
 Dhanwada Sudhaker Rao
Division of Endocrinology, Diabetes and Bone & Mineral Disorders, Henry Ford Hospital, Detroit, MI, USA
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
 07 September 2015Referee Report
doi:10.5256/f1000research.6864.r10217
 Malachi McKenna
St. Vincent's University Hospital, Dublin, Ireland
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Page 9 of 10











Reader Comment 30 Sep 2015
, University of Leicester, UKRaymond Dalgleish
I have noted a few issues in this article:
On page 2, in the section headed "Genes and classification", gene symbols (  and ) COLIA1 COL1A2
are inappropriately used to designate the component protein chains of type I collagen. Gene
symbols and protein product names should not be used interchangeably. The protein chains are
α1(I) and α2(I) respectively.
In Table 1, the gene symbols for the mutant genes leading to OI types I, II, III and IV are incorrect.
They should be  and , not  and .COL1A1 COL1A2 COL1A1 COLA2
In Table 1, the gene symbol for the gene encoding the protein prolyl-3 hydroxylase is , not P3H1
. The gene symbol for this gene was changed to  in December 2014.LEPRE1 P3H1
Table 1 continues to propagate the notion that there are very many OI types when, in reality, there
are really only five true types which can be clearly distinguished clinically (types I to V). The problem
has been caused by several new OI types being created to correspond to newly discovered genes
which harbour OI-causing sequence variants. This has only served to confuse matters and is
discussed at length by Van Dijk and Sillence (2014) (
).http://www.ncbi.nlm.nih.gov/pubmed/24715559
It is perhaps unsurprising that the article gives emphasis to pharmacological interventions for OI,
given that one of the authors is employed by Alexion Pharmaceuticals, but it is improper to ignore
surgical interventions such as rodding of long bones and mesenchymal stem cell therapy.
There is no mention in the article of the fact that there is a comprehensive database of gene variants
leading to OI: .https://oi.gene.le.ac.uk/
The list of OI genes is incomplete in Table 1. A comprehensive list of genes may be found at 
.https://oi.gene.le.ac.uk/status.php
 I declare that I curate the database of OI gene variants which in mentioned inCompeting Interests:
comment 6.
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